Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Summary

This phase II trial studies how well ibrutinib works in treating patients with B-cell acute lymphoblastic leukemia that has come back after treatment or has not responded to other treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2014-04

Primary completion

2015-11

Completion

2015-11

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual.”

Drugs

Indications